ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. We are focused on improving the safety of oral therapies for chronic disease.

Making Safer Drugs

Despite rigorous pre-approval testing of all pharmaceutical products, many approved drugs have serious and life threatening side effects that go undiscovered until the products have been launched and are in widespread use. ARYx's goal is to make these known therapeutic mechanisms safer by engineering out specific metabolic problems that cause toxic and dangerous side effects. Our novel drug products are carefully constructed and optimized to alter and improve metabolism while maintaining established efficacy.

ARM Technology

By applying our innovative and integrated ARM (ARYx RetroMetabolic Drug Design™) technology, we now have four drug candidates in the clinic and substantial opportunities to continue to broaden our product pipeline. Our current clinical compounds are:

Our proprietary ARM technology begins with a well-characterized drug with a known mechanism of action and toxicity profile, and then creates new drug candidates that exploit different metabolic pathways for elimination and excretion. This approach to drug design begins with the creation of a pharmacologically inactive, non-toxic, easily excreted end-product which we call “the ideal metabolite.” This structure is then utilized to engineer novel molecules designed to restore the efficacy of the parent structure but with a superior safety profile.

Our mission is to make proven therapies safer.